This report provides comprehensive information on the therapeutic development for Male Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Hypogonadism and special features on late-stage and discontinued projects.
The report enhances decision-making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Male Hypogonadism Overview
- Therapeutics Development
- Pipeline Products for Male Hypogonadism - Overview
- Pipeline Products for Male Hypogonadism - Comparative Analysis
- Male Hypogonadism - Therapeutics under Development by Companies
- Male Hypogonadism - Therapeutics under Investigation by Universities/Institutes
- Male Hypogonadism Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Male Hypogonadism - Products under Development by Companies
- Male Hypogonadism - Products under Investigation by Universities/Institutes
- Male Hypogonadism - Companies Involved in Therapeutics Development
- Antares Pharma, Inc.
- Clarus Therapeutics, Inc.
- Diurnal Limited
- EndoCeutics, Inc.
- Ferring International Center S.A.
- Forendo Pharma Limited
- Lipocine Inc.
- M et P Pharma AG
- Merck & Co., Inc.
- Mereo Biopharma Group Limited
- Millennium Pharmaceuticals, Inc.
- Monosol Rx, LLC
- Pantarhei Bioscience BV
- Repros Therapeutics Inc.
- Variant Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/t2k3k5/male_hypogonadism